Finanzen von AnaptysBio, Inc. (ANAB)ANABAnaptysBio, Inc.

AnaptysBio, Inc. (ANAB) generates its revenue primarily from Royalty Management, which accounts for 100.0% of total sales, equivalent to $25.56M. Understanding this concentration is critical for investors evaluating how ANAB navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, AnaptysBio, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 243.59%, while the net margin is 833.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ANAB converts its operational activities into shareholder value.

In the context of the broader market, ANAB competes directly with industry leaders such as COAG and KMDA. With a market capitalization of $1.43B, it holds a significant position in the sector. When comparing efficiency, ANAB's gross margin of 100.00% stands against COAG's N/A and KMDA's 40.91%. Such benchmarking helps identify whether AnaptysBio, Inc. is trading at a premium or discount relative to its financial performance.

AnaptysBio reported a significant profit rebound with a net income of $183.88 million for Q2 2026, largely due to a tax benefit. However, the company has faced inconsistent earnings, with a GAAP EPS of -$1.84 in Q1 2026, missing expectations by $1.04.